Psicofarma

What Psicofarma does

Psicofarma SA de CV is a privately held Mexican pharmaceutical laboratory founded in 1974 by a group of psychiatrists to address mental-health treatment gaps in Mexico. The company specializes in central nervous system (CNS) medications and operates a portfolio of approximately 43 products across 108 presentations covering depression, anxiety, schizophrenia, bipolar disorder, ADHD, Parkinson's disease, epilepsy, migraine, neuropathic pain, oncology pain, and addictions. The company self-describes as holding leadership in the Mexican CNS prescription market.

Its operations are anchored by a state-of-the-art manufacturing plant in Vallejo, Mexico City (headquarters at Calzada de Tlalpan 4369, Toriello Guerra), and a newer injectable manufacturing facility at División del Norte. Three internal centers support the value chain: CEDPROF handles reformulation and development of differentiated dosage forms; CIDAT conducts pharmacovigilance, EEG/ECG diagnostic studies, and Phase I–IV clinical trial monitoring in compliance with NOM-220-SSA1-2016; and CIM maintains a bibliographic database of pharmacokinetic, pharmacodynamic, and therapeutic data for prescribers. The company invests 10% of sales in R&D and operates a pharmacovigilance unit with direct patient contact channels.

Psicofarma generates revenue primarily through one-time prescription-pharmaceutical sales distributed via psychiatrist and neurologist prescribing channels and dispensed through Mexican pharmacies. Pricing is not publicly disclosed and is determined through healthcare providers, pharmacies, and institutional purchasing agreements. The company targets healthcare professionals as primary customers, with patient end-users as secondary beneficiaries, and reaches them through dedicated web portals (Contigo en Mente for medical professionals and patients), social media (Facebook, Twitter), and direct engagement. Geographic scope is 100% domestic, with no claimed international footprint. Multiple ISO certifications (9001:2015, 14001:2015, 45001:2018) and a 12-consecutive-year Distintivo ESR (2011–2022) provide regulatory and ESG positioning.

Name

Psicofarma

Legal name

Psicofarma SA de CV

Website

https://psicofarma.com.mx

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Psicofarma is a privately held Mexican pharmaceutical laboratory founded in 1974 that manufactures and sells approximately 43 specialized CNS prescription products across 108 presentations for Mexican psychiatrists, neurologists, and patients, supported by in-house R&D, pharmacovigilance, and clinical research centers.

Ownership category

akta.pro rank

Product category

CNS Pharmaceuticals

NAICS

Professional, Scientific, and Technical Services (54)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Central nervous system pharmaceuticals
• Psychiatric medications manufacturing
• Neurological disorder treatments
• Prescription drug manufacturing
• Mental health medications

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Psicofarma generates revenue through the manufacture and sale of prescription medications specializing in central nervous system treatments, psychiatric, neurological, and algological conditions. Products are distributed through healthcare professionals and pharmacies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Psicofarma SA de CV is a 100% Mexican pharmaceutical laboratory that manufactures and sells prescription medications specialized in central nervous system (CNS) disorders, including psychiatric, neurological, and algological conditions. The company offers approximately 43 products across 108 presentations covering depression, anxiety, schizophrenia, bipolar disorder, ADHD, Parkinson's, epilepsy, migraine, neuropathic pain, oncology pain, and addictions, supported by in-house R&D (CEDPROF), pharmacovigilance (CIDAT), and drug information (CIM) centers.

Product overview

Psicofarma is a 100% Mexican pharmaceutical laboratory founded in 1974 by psychiatrists to address mental health needs. The company operates as a single unified product portfolio centered on specialized CNS (Central Nervous System) medications, with approximately 43 products in 108 presentations. The core product line addresses Depression, Anxiety, Schizophrenia, Bipolar Disorder, ADHD, Parkinson's, Epilepsy, Migraine, Neuropathic Pain, Oncology Pain, and Addictions. The portfolio is supported by three specialized research and service centers: CEDPROF (differentiated product R&D), CIDAT (pharmacovigilance and clinical research), and CIM (drug information center). Related group sites include Contigo en Mente (patient/physician portal) and sister companies Neolpharma and Alpharma.

Differentiator

Problem solved

Functional benefit

Products and services

• CNS Medications Portfolio

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Instituto Nacional de Neurología y NeurocirugíacoreStrategic or Co-development PartnerResearch collaboration with one of Mexico's premier neurology and neurosurgery institutions for improving treatments for chronic diseases affecting the population.
• Instituto de Investigaciones Biomédicas de la UNAMcoreStrategic or Co-development PartnerPartnership with UNAM's Biomedical Research Institute for advancing research in chronic diseases and neurological conditions.
• Instituto Nacional de CancerologíacoreStrategic or Co-development PartnerCollaboration with Mexico's National Cancer Institute for cancer treatment research and development.
• Hospital Infantil de MéxicocoreStrategic or Co-development PartnerPartnership with Mexico's Children's Hospital for pediatric healthcare and pharmaceutical research.
• Instituto Nacional de RehabilitacióncoreStrategic or Co-development PartnerResearch collaboration with Mexico's National Rehabilitation Institute.
• Universidad Nacional Autónoma de México (FES-Zaragoza)coreStrategic or Co-development PartnerEducational partnership with UNAM's FES-Zaragoza for improving academic and professional development of physicians interested in the pharmaceutical field.
• Hospital GeneralminorStrategic or Co-development PartnerCollaboration for development of various clinical protocols.
• Hospital JuárezminorStrategic or Co-development PartnerCollaboration for development of various clinical protocols.
• Instituto Mexicano del Seguro Social (IMSS)minorStrategic or Co-development PartnerCollaboration for development of various clinical protocols.
• ISSSTEminorStrategic or Co-development PartnerCollaboration for development of various clinical protocols.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Laboratorios Liomont: Liomont is a 100% Mexican pharmaceutical laboratory with a broad product portfolio including CNS, anti-infectives, and metabolic therapies. As a comparable domestic Mexican specialty/generics manufacturer, it competes directly with Psicofarma for institutional tenders and physician prescriptions.
• Grupo PiSA (PiSA Farmacéutica): PiSA is one of Mexico's largest pharmaceutical groups, with a broad portfolio spanning CNS, cardiology, and specialty therapies. It is a domestic specialty competitor that overlaps with Psicofarma in psychiatric and neurological therapeutic areas within Mexico.
• Lundbeck: Lundbeck is a global pharmaceutical company specialized in central nervous system disorders, with a portfolio covering depression, anxiety, schizophrenia, epilepsy, and Parkinson's. It is the most direct global CNS specialty competitor to Psicofarma, sharing therapeutic focus and prescriber base in Mexico.
• Laboratorios Silanes: Silanes is a Mexican pharmaceutical company with a CNS-focused portfolio (including depression, anxiety, and neurology treatments) and significant institutional presence. It directly competes with Psicofarma in Mexican CNS prescriptions and public-sector tenders.

Broad incumbents

• Eli Lilly (Mexico operations): Eli Lilly operates a global CNS franchise (Cymbalta, Strattera, Zyprexa) that directly competes with Psicofarma's psychiatric and neurological portfolio. As a multinational incumbent, Lilly has substantially greater R&D resources and originator evidence in the same therapeutic categories.
• Sanofi (Mexico operations): Sanofi operates a broad pharmaceutical portfolio in Mexico that includes CNS products (including legacy CNS assets). It competes with Psicofarma for psychiatrist and neurologist prescriptions, with greater international R&D and marketing resources.
• AbbVie (Mexico operations): AbbVie has a global CNS franchise including depression and neurology products that compete with Psicofarma's portfolio in Mexico. Its resources for clinical research, prescriber marketing, and originator launches exceed those of domestic specialty players.
• Pfizer (Mexico operations): Pfizer maintains a broad CNS portfolio (Effexor, Lyrica, Neurontin legacy products) and competes with Psicofarma across multiple categories including depression, anxiety, epilepsy, and neuropathic pain in Mexico. As a global incumbent, Pfizer brings greater clinical evidence and KOL engagement.
• Novartis (Mexico operations): Novartis operates across multiple therapeutic areas including neurology (e.g., migraine, multiple sclerosis) in Mexico, with originator products that compete with Psicofarma's neurology franchise. As a global incumbent, Novartis has substantially greater commercial and clinical-trial resources.
• GSK (Mexico operations): GSK maintains a pharmaceutical portfolio in Mexico with CNS-adjacent products and competes for institutional and retail prescriptions. As a multinational incumbent, it offers broader resources than domestic specialty players like Psicofarma.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/psicofarma
• Facebookfacebook.com/PsicofarmaSaludMental
• LinkedInlinkedin.com/company/psicofarma

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psicofarma